CHF 150k · Other round · Healthtech · Epalinges, Switzerland
Epalinges-based Connected Health Development (CHD), which is developing remote maternal and fetal monitoring technology, has secured CHF 150k in Venture Kick support. Tech.eu reports that the funding will support development, testing and validation of MONI2, CHD's system for monitoring high-risk pregnancies outside hospital settings.
The CHF 150k is Venture Kick's full three-stage support package, not a conventional priced round. The programme's terms divide it into a CHF 10k grant, a CHF 40k convertible loan and a CHF 100k convertible loan. CHD had already announced the second stage in June, so the headline figure should not be read as CHF 150k of entirely new equity.
Validation is the next commercial milestone
MONI2 combines a washable smart-textile belt with a patient app and a secure web portal for clinicians. CHD says the belt is designed to capture maternal and fetal ECG, uterine contractions and fetal movements, while the software presents basic indicators to the patient and more detailed data to healthcare professionals. The intended customer is therefore a care provider that needs usable clinical information from a device worn at home, not simply a consumer buying another pregnancy wearable.
That end-to-end design matters commercially. Remote monitoring can reduce some routine hospital visits only if the hardware is comfortable enough to be worn correctly, the signal is reliable enough to support decisions and the resulting information fits clinicians' working practices. A failure in any one layer weakens the value of the whole service. The current funding is aimed at prototypes and validation, which makes it preparation capital for those proof points rather than evidence that MONI2 is already approved or in commercial use.
The model could combine kit sales with recurring software or monitoring subscriptions. CHD targets more than 30,000 kits and subscriptions over four years, but that is a company forecast. Reaching it will depend on clinical validation, regulatory clearance, manufacturing consistency and care-provider adoption. The useful near-term measure is not the forecast itself, but whether the company can turn a functional prototype into dependable data that clinicians will act on.
A staged package matches an early device roadmap
CHD was incorporated in 2026 and is based at Biopôle in Epalinges. Biopôle describes the company as a medtech and e-health service operator working on remote monitoring for pregnant women at risk. Venture Kick's staged structure puts relatively small amounts behind successive development checkpoints. For CHD, the next financing question is whether prototype and validation progress can support the wider seed round that the company has been pursuing, without presenting planned investor commitments as completed funding.
Sources checked:
Tech.eu · Venture Kick programme terms · Venture Kick Stage II announcement · CHD announcement · Biopôle profile · Tech.eu Funding Explorer
